Biologic Response Modifier Therapy for Psoriatic Ocular Inflammatory Disease

• Published in: Ocular immunology and inflammation Vol. 16; no. 3; pp. 89 - 93
• Main Authors: Huynh, Nancy, Cervantes-Castañeda, Rene A., Bhat, Pooja, Gallagher, Michael J., Foster, C. Stephen
• Format: Journal Article
• Language: English
• Published: England Informa UK Ltd 01.01.2008; Taylor & Francis
• Subjects: Adalimumab; Adult; Aged; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Biological Therapy - adverse effects; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infliximab; Male; Methotrexate - therapeutic use; Middle Aged; ocular inflammation; psoriasis; Psoriasis - complications; Remission Induction; Scleritis - drug therapy; Scleritis - etiology; Scleritis - physiopathology; Treatment Outcome; tumor necrosis factor alpha inhibitors; Uveitis - drug therapy; Uveitis - etiology; Uveitis - physiopathology; Visual Acuity - drug effects
• ISSN: 0927-3948; 1744-5078
• DOI: 10.1080/09273940802023786

Purpose: To evaluate the efficacy and safety of biologic response modifiers (BRMs) in the treatment of patients with psoriatic ocular inflammatory disease. Methods: The records of 8 patients diagnosed with psoriatic ocular inflammatory disease who received adalimumab or infliximab were reviewed. Main outcome measures were control of intraocular inflammation, visual acuities, and adverse effects of therapy. Results: The mean patient age was 53 ± 15 years. Three patients had psoriatic panuveitis, 3 had psoriatic scleritis, and 2 patients had psoriatic anterior uveitis. The ocular inflammatory disease was bilateral in 7 patients. Four patients received adalimumab, and 4 received infliximab. Average time of therapy was 6.1 ± 4.7 months. Six patients were treated concurrently with methotrexate. With respect to visual acuity, 2 patients demonstrated improvement, 2 patients demonstrated deterioration, and 4 patients remained stable. Seven patients achieved remission of their ocular inflammation. Conclusions: BMRs can be a useful adjunctive therapy for psoriatic ocular inflammatory disease.